Genetics in the diagnosis and treatment of cardiovascular diseases

Abstract

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide, with genetics being a major risk factor. Genetic cardiovascular disease can occur either because of single variant (Mendelian) or polygenic influences and has been linked to inherited cardiovascular conditions (ICC) such as arrhythmias, cardiomyopathies, dyslipidemias, and aortopathies which are significant factors leading to sudden cardiac death in young adults. Timely screening, diagnosis, and management of ICC can not only provide life-saving treatment to a patient, but also identify at-risk family members. The field of pharmacogenomics (PGx) helped to understand the variable action of medications such as clopidogrel, aspirin, warfarin, and statin according to genotype. Newer technologies such as multi-omics can combine data from multiple sources such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiome. These advancements can contribute to the development of polygenic prediction scores and precision medicine tailored to individual genotypes. Substantial strides have been made in genetic-based therapeutics, gene editing technologies, and drug delivery systems, which have significantly expanded treatment options for patients with acquired or inherited CVDs. Although variable, the country- and society-specific guidelines on genetic testing for ICC and PGx and treatment are being continuously updated to keep up with ongoing research in the field. Along with appropriate knowledge, other factors including cost and availability of genetic testing play a vital role in the usage by both physicians and patients. With the advent of newer genetic testing for CVDs, a key factor is the availability of genetic counselors (GCs) who are specifically trained in cardiovascular genomics. The current review provides a concise summary of the major influences of genetics in the diagnosis and treatment of CVDs.

Keywords

Cardiovascular genetics / pharmacogenomics / inherited cardiovascular diseases / genetic counseling

References

[1] World Health Organization. Cardiovascular diseases (CVDs) Fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [Last accessed on 12 Apr 2024]

[2] Castrichini M,Pereira N.Pharmacogenetics of antiplatelet therapy.Annu Rev Pharmacol Toxicol2023;63:211-29 PMCID:PMC9868113

[3] Wang RS,Loscalzo J.Multiomics network medicine approaches to precision medicine and therapeutics in cardiovascular diseases.Arterioscler Thromb Vasc Biol2023;43:493-503 PMCID:PMC10038904

[4] Ross S,Paré G.Pharmacogenomics in stroke and cardiovascular disease: state of the art.Stroke2023;54:270-8

[5] Kuang Z,Tan Y,Li J.MicroRNA in the diagnosis and treatment of doxorubicin-induced cardiotoxicity.Biomolecules2023;13:568 PMCID:PMC10046787

[6] Christiansen MK,Jensen HK.Polygenic risk scores in coronary artery disease.Curr Opin Cardiol2023;38:39-46

[7] Sethi Y,Kaka N.Precision medicine and the future of cardiovascular diseases: a clinically oriented comprehensive review.J Clin Med2023;12:1799 PMCID:PMC10003116

[8] Catchpool M,Martyn M.A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy.Genet Med2019;21:2815-22 PMCID:PMC6892743

[9] Kasztura M,Bempong NE,Flahault A.Cost-effectiveness of precision medicine: a scoping review.Int J Public Health2019;64:1261-71 PMCID:PMC6867980

[10] Kiflen M,Mao S.Cost-effectiveness of polygenic risk scores to guide statin therapy for cardiovascular disease prevention.Circ Genom Precis Med2022;15:e003423

[11] Wronska A.The role of microRNA in the development, diagnosis, and treatment of cardiovascular disease: recent developments.J Pharmacol Exp Ther2023;384:123-32

[12] Vaskova E,Tada Y,Mercola M.Sacubitril/Valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal miR-181a in a rodent chronic myocardial infarction model.J Am Heart Assoc2020;9:e015640 PMCID:PMC7670523

[13] Stojkovic S,Sulzgruber P.Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure.Int J Cardiol2020;303:80-5

[14] Wang H,Tao T.Identification of microRNA biomarkers in serum of patients at different stages of atrial fibrillation.Heart Lung2020;49:902-8

[15] Bejleri J,Donovan P,Pfeiffer S.Diagnostic and prognostic circulating microrna in acute stroke: a systematic and bioinformatic analysis of current evidence.J Stroke2021;23:162-82 PMCID:PMC8189849

[16] Pérez-Cremades D,Assa C.MicroRNA-mediated control of myocardial infarction in diabetes.Trends Cardiovasc Med2023;33:195-201 PMCID:PMC9288556

[17] Bhatti JS,Vijayvergiya R,Bhatti GK.Mitochondrial miRNA as epigenomic signatures: visualizing aging-associated heart diseases through a new lens.Ageing Res Rev2023;86:101882

[18] Guo YT,Xu YL.The effects of microRNAs in the development of heart failure.Curr Cardiol Rep2023;25:747-59

[19] Samra M.Non-coding RNA and their potential role in cardiovascular diseases.Gene2023;851:147011

[20] Long Q,Jiang S.The landscape of circular RNAs in cardiovascular diseases.Int J Mol Sci2023;24:4571 PMCID:PMC10003248

[21] Joaquim VHA,Fernandes T.Circular RNAs as a diagnostic and therapeutic target in cardiovascular diseases.Int J Mol Sci2023;24:2125 PMCID:PMC9916891

[22] Wang K,Wang T.The function and therapeutic potential of circular RNA in cardiovascular diseases.Cardiovasc Drugs Ther2023;37:181-98

[23] Neufeldt D,Bär C.Circular RNAs at the intersection of cancer and heart disease: potential therapeutic targets in cardio-oncology.Cardiovasc Res2023;119:1495-508

[24] Singh DD,Choi SA,Yadav DK.Clinical significance of microRNAs, long non-coding rnas, and circRNAs in cardiovascular diseases.Cells2023;12:1629 PMCID:PMC10297435

[25] Sánchez-Cabo F,Silla-Castro JC.Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study.Eur Heart J2023;44:2698-709 PMCID:PMC10393076

[26] Solari FA,Swieringa F.Multi-omics approaches to study platelet mechanisms.Curr Opin Chem Biol2023;73:102253

[27] Ferrucci L,Ubaida-Mohien C.Transcriptomic and proteomic of gastrocnemius muscle in peripheral artery disease.Circ Res2023;132:1428-43 PMCID:PMC10213145

[28] Nurmohamed NS,Mayr M.Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction.Eur Heart J2023;44:1594-607 PMCID:PMC10163980

[29] Garmany R,Tester DJ.Multi-omic architecture of obstructive hypertrophic cardiomyopathy.Circ Genom Precis Med2023;16:e003756

[30] Moore J,Venturini G.Multi-omics profiling of hypertrophic cardiomyopathy reveals altered mechanisms in mitochondrial dynamics and excitation-contraction coupling.Int J Mol Sci2023;24:4724 PMCID:PMC10002553

[31] Rega S,Bouhuis S.Multi-omics in thoracic aortic aneurysm: the complex road to the simplification.Cell Biosci2023;13:131 PMCID:PMC10357728

[32] Hasman M,Theofilatos K.Uncovering protein networks in cardiovascular proteomics.Mol Cell Proteom2023;22:100607 PMCID:PMC10460687

[33] Li Z,Mills NL.A multimodal omics framework to empower target discovery for cardiovascular regeneration.Cardiovasc Drugs Ther2024;38:223-36 PMCID:PMC10959818

[34] Adua E.Decoding the mechanism of hypertension through multiomics profiling.J Hum Hypertens2023;37:253-64 PMCID:PMC10063442

[35] Maiorino E.Phenomics and robust multiomics data for cardiovascular disease subtyping.Arterioscler Thromb Vasc Biol2023;43:1111-23 PMCID:PMC10330619

[36] Safabakhsh S,Miller CL.Cardiovascular utility of single cell RNA-Seq.Curr Opin Cardiol2023;38:193-200

[37] Miranda AMA,Maatz H.Single-cell transcriptomics for the assessment of cardiac disease.Nat Rev Cardiol2023;20:289-308

[38] Wang S,Yuan L.tRNA-derived small rnas: novel insights into the pathogenesis and treatment of cardiovascular diseases.J Cardiovasc Transl Res2023;16:300-9

[39] Balachander K,Roy A.Emerging role of RNA m5C modification in cardiovascular diseases.J Cardiovasc Transl Res2023;16:598-605

[40] Yin Y,Han L.The hippo kinases MST1/2 in cardiovascular and metabolic diseases: a promising therapeutic target option for pharmacotherapy.Acta Pharm Sin B2023;13:1956-75 PMCID:PMC10213817

[41] Shao Y,Sun L,Xu J.MST1: A future novel target for cardiac diseases.Int J Biol Macromol2023;239:124296

[42] Cai Y,Shao C,Li L.Role of galectin-3 in vascular calcification.Glycoconj J2023;40:149-58

[43] Emami Meybodi SM,Yari A.Circulatory long noncoding RNAs (circulatory-LNC-RNAs) as novel biomarkers and therapeutic targets in cardiovascular diseases: implications for cardiovascular diseases complications.Int J Biol Macromol2023;225:1049-71

[44] Ao X,Li X.Non-coding RNAs regulating mitochondrial function in cardiovascular diseases.J Mol Med2023;101:501-26

[45] Heshmatzad K,Maleki M.Role of non-coding variants in cardiovascular disease.J Cell Mol Med2023;27:1621-36 PMCID:PMC10273088

[46] Jiang X.Extracellular lncRNAs secreted and absorbed by cardiomyocytes.J Cell Biochem2023;124:785-96

[47] Zhu Y,Wang X.RNA-based therapeutics: an overview and prospectus.Cell Death Dis2022;13:644 PMCID:PMC9308039

[48] Gareri C,Giordano S,Curcio A.Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias.J Clin Med2022;11:3884 PMCID:PMC9267663

[49] Yeang C,Su F.Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol.J Am Coll Cardiol2022;79:1035-46

[50] Kim Y,Sarsenova M,Saparov A.Recent advances in gene therapy for cardiac tissue regeneration.Int J Mol Sci2021;22:9206 PMCID:PMC8431496

[51] Brown EE.A Practical guide to genetic testing in inherited heart disease.Card Electrophysiol Clin2023;15:241-7

[52] Bowen JM,Johnson DS.Diagnosis and management of vascular Ehlers-Danlos syndrome: experience of the UK national diagnostic service, Sheffield.Eur J Hum Genet2023;31:749-60 PMCID:PMC10326011

[53] Giuliani L,Urtis M.Prevalence and complications of aberrant subclavian artery in patients with heritable and nonheritable arteriopathies.J Am Coll Cardiol2023;81:979-91

[54] Specterman MJ.Cardiogenetics: the role of genetic testing for inherited arrhythmia syndromes and sudden death.Heart2023;109:434-41

[55] Asad ZUA,Roman D,Stavrakis S.Same gene, different story (a case report of congenital long QT syndrome subtype 8 with a novel mutation).Am J Cardiol2023;200:13-7

[56] Auricchio A,Özkartal T.Role of genetic testing in young patients with idiopathic atrioventricular conduction disease.Europace2023;25:643-50 PMCID:PMC9934995

[57] Lalaguna L,Priori SG.Genome editing and inherited cardiac arrhythmias. In: Xiao J, editor. Genome editing in cardiovascular and metabolic diseases. Singapore: Springer Nature; 2023. pp. 115-27.

[58] Lloyd-Jones DM,Leip EP.Lifetime risk for development of atrial fibrillation: the Framingham heart study.Circulation2004;110:1042-6

[59] Sagris M,Theofilis P,Oikonomou E.Atrial fibrillation: pathogenesis, predisposing factors, and genetics.Int J Mol Sci2021;23:6 PMCID:PMC8744894

[60] Kontorovich AR.Approaches to genetic screening in cardiomyopathies: practical guidance for clinicians.JACC Heart Fail2023;11:133-42 PMCID:PMC10191168

[61] Brodehl A.Genetic insights into primary restrictive cardiomyopathy.J Clin Med2022;11:2094 PMCID:PMC9027761

[62] Mansoori GA,Wani S.Introducing and implementing genetic assessment in cardio-obstetrics clinical practice: clinical and genetic workup of patients with cardiomyopathy.Int J Mol Sci2023;24:9119 PMCID:PMC10252198

[63] Koslow M,Xu X.Transcriptome studies of inherited dilated cardiomyopathies.Mamm Genome2023;34:312-22 PMCID:PMC10426000

[64] Ehrlich L.Copy-number variation in congenital heart disease.Curr Opin Genet Dev2022;77:101986

[65] Dotzler SM,Gendron WAC.Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome.Circulation2021;143:1411-25

[66] Yamamoto Y,Harita T.Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation.Hum Mol Genet2017;26:1670-7

[67] Vermersch E,Hulot JS.CRISPR/Cas9 gene-editing strategies in cardiovascular cells.Cardiovasc Res2020;116:894-907

[68] Liu N.CRISPR modeling and correction of cardiovascular disease.Circ Res2022;130:1827-50 PMCID:PMC9202442

[69] Kohaut E,Rooryck C.Morphological and genetic causes of fetal cardiomyopathies.Clin Genet2023;104:63-72

[70] Lawley CM.Clinical and genetic screening for hypertrophic cardiomyopathy in paediatric relatives: changing paradigms in clinical practice.J Clin Med2023;12:2788 PMCID:PMC10146293

[71] Sheppard MN,Banner J.Association for European Cardiovascular Pathology (AECVP)Genetically determined cardiomyopathies at autopsy: the pivotal role of the pathologist in establishing the diagnosis and guiding family screening.Virchows Arch2023;482:653-69 PMCID:PMC10067659

[72] Robles-Mezcua A,Medina-Palomo C.The novel variant NP_00454563.2 (p.Glu259Glyfs*77) in gene PKP2 associated with arrhythmogenic cardiomyopathy in 8 families from Malaga, Spain.Genes2023;14:1468 PMCID:PMC10379208

[73] Christensen KD,Galbraith LN.Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: estimates from the PreEMPT model.Genet Med2023;25:100797 PMCID:PMC10168130

[74] Burns C,Sweeting J,Ingles J.Evaluating a communication aid for return of genetic results in families with hypertrophic cardiomyopathy: a randomized controlled trial.J Genet Couns2023;32:425-34 PMCID:PMC10946474

[75] Chang CS,Kim SY.Prevalence of associated extracardiac anomalies in prenatally diagnosed congenital heart diseases.PLoS One2021;16:e0248894 PMCID:PMC7971844

[76] Formigari R,Digilio MC.Genetic syndromes and congenital heart defects: how is surgical management affected?.Eur J Cardiothorac Surg2009;35:606-14

[77] Brunham LR.What Is the Prevalence of familial hypercholesterolemia?.Arterioscler Thromb Vasc Biol2021;41:2629-31

[78] Knowles JW,Greendale K.Reducing the burden of disease and death from familial hypercholesterolemia: a call to action.Am Heart J2014;168:807-11 PMCID:PMC4683103

[79] Lagace TA.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Curr Opin Lipidol2014;25:387-93 PMCID:PMC4166010

[80] Chambergo-Michilot D,Kulkarni S.Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes.Vasc Health Risk Manag2022;18:73-80 PMCID:PMC8880726

[81] Wiegman A,Ali S.Evinacumab for pediatric patients with homozygous familial hypercholesterolemia.Circulation2024;149:343-53 PMCID:PMC10814999

[82] Adam RC,Alexa-Braun CA.Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance.J Lipid Res2020;61:1271-86 PMCID:PMC7469887

[83] Karwatowska-Prokopczuk E,Yan JH.Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.J Clin Lipidol2023;17:181-8

[84] Koren MJ,Baum SJ.Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).Nat Med2022;28:96-103

[85] Kalia I,Reilly M.Addressing the underdiagnosis of familial hypercholesterolemia: a mixed methods study exploring the knowledge and practice behaviors of cardiology healthcare providers.J Clin Transl Sci2023;7:e92 PMCID:PMC10130828

[86] Shuldiner AR,Bliden KP.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA2009;302:849-57 PMCID:PMC3641569

[87] Gurbel PA,Shuldiner AR.Genotyping: one piece of the puzzle to personalize antiplatelet therapy.J Am Coll Cardiol2010;56:112-6

[88] Tantry US,Wei C.First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.Circ Cardiovasc Genet2010;3:556-66

[89] Mega JL,Collet JP.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.JAMA2010;304:1821-30 PMCID:PMC3048820

[90] Gurbel PA,Antonino MJ.The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.J Thromb Haemost2010;8:43-53

[91] Gurbel PA,Bliden KP,Pakyz RE.The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.Am Heart J2011;161:598-604 PMCID:PMC3061841

[92] Jeong YH,Kim IS.Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.Circ Cardiovasc Interv2011;4:585-94

[93] Price MJ,Gurbel PA.The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y₁₂ inhibitors.Rev Cardiovasc Med2011;12:1-12

[94] Gurbel PA,Tantry US.Personalized antiplatelet therapy: state of the art.JRSM Cardiovasc Dis2012;1:1-10 PMCID:PMC3738365

[95] Gurbel PA.Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?.Circulation2012;125:1276-87

[96] Tantry US,Navarese EP,Gurbel PA.Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Expert Rev Cardiovasc Ther2013;11:447-62

[97] Jeong YH,Tantry US.Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study.J Thromb Haemost2013;11:1194-7

[98] Erlinge D,Duvvuru S.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.Thromb Haemost2014;111:943-50

[99] Gurbel PA,Tantry US.The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.Thromb Haemost2014;112:589-97

[100] Jeong YH,Shuldiner AR,Gurbel PA.Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.Thromb Haemost2014;111:713-24

[101] Doll JA,Roe MT.TRILOGY ACS InvestigatorsImpact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel.J Am Coll Cardiol2016;67:936-47

[102] Winter MP,De Caterina R.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Eur Heart J Cardiovasc Pharmacother2017;3:221-34

[103] Verma SS,Gong L.ICPC InvestigatorsGenomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium.Clin Pharmacol Ther2020;108:1067-77

[104] Lewis JP,Reny JL.ICPC InvestigatorsPharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.Eur Heart J Cardiovasc Pharmacother2020;6:203-10 PMCID:PMC7363022

[105] Shawky A,Nazih M,El-Zawahry M.CYP2C19 polymorphism in ischemic heart disease patients taking clopidogrel after percutaneous coronary intervention in Egypt.J Epidemiol Glob Health2023;13:374-83 PMCID:PMC10272067

[106] Mehta MP,Patel RJ,Shah GB.Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Indian J Pharmacol2023;55:27-33 PMCID:PMC10204895

[107] Thomas CD,Lee CR.Pharmacogenetics of P2Y(12) receptor inhibitors.Pharmacotherapy2023;43:158-75 PMCID:PMC9931684

[108] Berg JM, van den Broek WWA. Another step toward CYP2C19 genotype-guided therapy in treatment with dual antiplatelet therapy.JACC Cardiovasc Interv2023;16:826-8

[109] Levens AD,Jukema JW.Feasibility of community pharmacist-initiated and point-of-care CYP2C19 genotype-guided de-escalation of oral P2Y12 inhibitors.Genes2023;14:578 PMCID:PMC10048116

[110] Dong OM,Chanfreau-Coffinier C.Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.Eur Heart J Qual Care Clin Outcomes2023;9:249-57 PMCID:PMC10272926

[111] Koufaki MI,Díaz-Villamarín X.Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study.Hum Genomics2023;17:51 PMCID:PMC10249170

[112] Silva GFD,Moser V.Impact of pharmacogenetics on aspirin resistance: a systematic review.Arq Neuropsiquiatr2023;81:62-73 PMCID:PMC10014202

[113] Herrera-Galeano JE,Wilson AF.A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability.Arterioscler Thromb Vasc Biol2008;28:1484-90 PMCID:PMC2739240

[114] Lewis JP,Xie S.Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population.Clin Pharmacol Ther2020;108:1289-98 PMCID:PMC7959328

[115] Friede KA,Gales J.An antiplatelet response gene expression signature is associated with bleeding.Cardiovasc Res2023;119:551-60 PMCID:PMC10226737

[116] Tidbury N,Lip GYH.Lessons learned from the influence of CYP2C9 genotype on warfarin dosing.Expert Opin Drug Metab Toxicol2023;19:185-8

[117] Liu TY,You YS.Efficacy of warfarin therapy guided by pharmacogenetics: a real-world investigation among han taiwanese.Clin Ther2023;45:662-70

[118] Šimičević L,Kirhmajer MV.Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: case series.Pharmacy2023;11:29 PMCID:PMC9966833

[119] Thompson LE,Narayan R,Brown TM.Personalizing direct oral anticoagulant therapy for a diverse population: role of race, kidney function, drug interactions, and pharmacogenetics.Clin Pharmacol Ther2023;113:585-99 PMCID:PMC9852362

[120] Massmann A,Green RC.SLCO1B1 gene-based clinical decision support reduces statin-associated muscle symptoms risk with simvastatin.Pharmacogenomics2023;24:399-409 PMCID:PMC10242433

[121] Shatnawi A,Al-Share Q.Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety.Per Med2023;20:65-86

[122] AlAzzeh O.The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing.Pharmacogenomics2023;24:173-82 PMCID:PMC10072122

[123] Alrajeh K.The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing.Pharmacogenomics2023;24:15-26 PMCID:PMC9979151

[124] Tornio A,Siddiqui MK.The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial.Front Pharmacol2023;14:1090010 PMCID:PMC10043296

[125] Valverde-Hernández JC,Chavarría-Soley G,Campos-Sánchez R.Frequencies of variants in genes associated with dyslipidemias identified in Costa Rican genomes.Front Genet2023;14:1114774 PMCID:PMC10098023

[126] Dawed AY,Brown A.DIRECT consortiumPharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.Lancet Diabetes Endo2023;11:33-41

[127] Sarhan N,Alsahali S.Impact of vitamin D supplementation on the clinical outcomes and epigenetic markers in patients with acute coronary syndrome.Pharmaceuticals2023;16:262 PMCID:PMC9967129

[128] Oluwole OG.Genomic medicine in Africa: a need for molecular genetics and pharmacogenomics experts.Curr Med Res Opin2023;39:141-7

[129] Oni-Orisan A,Hoffecker G.Pharmacogenomics Global Research Network (PGRN) Publications CommitteeAn introductory tutorial on cardiovascular pharmacogenetics for healthcare providers.Clin Pharmacol Ther2023;114:275-87 PMCID:PMC10406163

[130] Saleh A,Pereira N.Pharmacogenetics of cardiovascular drugs.Curr Opin Cardiol2023;38:207-14

[131] Nogueiras-Álvarez R.Pharmacogenomics in clinical trials: an overview.Front Pharmacol2023;14:1247088 PMCID:PMC10625420

[132] Tardif JC,Dubé MP.Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.Eur Heart J2022;43:5062-3

[133] Ommen SR,Burke MA.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines.Circulation2020;142:e558-631

[134] Musunuru K,Day SM.Genetic testing for inherited cardiovascular diseases: a scientific statement from the American heart association.Circ Genom Precis Med2020;13:e000067

[135] Landstrom AP,Gelb BD.Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the American heart association.Circ Genom Precis Med2021;14:e000086 PMCID:PMC8546375

[136] Isselbacher EM,Hamilton Black J 3rd.2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines.Circulation2022;146:e334-482

[137] Landstrom AP,Ackerman MJ.Interpreting incidentally identified variants in genes associated with heritable cardiovascular disease: a scientific statement from the American heart association.Circ Genom Precis Med2023;16:e000092

[138] Wilde AAM,Márquez MF.European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases.Europace2022;24:1307-67

[139] Genetic testing for cardiac disease. Available from: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/oxford/gene-expression-tests-cardiac-conditions-ohp.pdf [Last accessed on 12 Apr 2024]

[140] Genetic testing for cardiovascular disease. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39084&ver=5 [Last accessed on 12 Apr 2024]

[141] GeneDx. Genetic testing for cardiovascular disease. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39084&ver=5#:~:text=However%2C%20Medicare%20does%20not%20cover,diagnostic%20result%20in%20most%20circumstances [Last accessed on 15 Apr 2024]

[142] Abdullah-Koolmees H,Nijenhuis M.Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines.Front Pharmacol2020;11:595219 PMCID:PMC7868558

[143] Tayeh MK,Goetz MP.ACMG Laboratory Quality Assurance CommitteeElectronic address: [e-mail]. Clinical pharmacogenomic testing and reporting: a technical standard of the American College of Medical Genetics and Genomics (ACMG).Genet Med2022;24:759-68

[144] Table of pharmacogenetic associations. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations [Last accessed on 12 Apr 2024]

[145] Johnson JA,Gong L.Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 Update.Clin Pharmacol Ther2017;102:397-404 PMCID:PMC5546947

[146] Sibbing D,Alexopoulos D.Updated expert consensus statement on platelet function and genetic testing for Guiding P2Y₁₂ receptor inhibitor treatment in percutaneous coronary intervention.JACC Cardiovasc Interv2019;12:1521-37

[147] Lee CR,Sangkuhl K.Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update.Clin Pharmacol Ther2022;112:959-67 PMCID:PMC9287492

[148] Cooper-DeHoff RM,Ramsey LB.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms.Clin Pharmacol Ther2022;111:1007-21 PMCID:PMC9035072

[149] MolDX: pharmacogenomics testing. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38294&ver=16 [Last accessed on 12 Apr 2024]

[150] Pritchard D,Stephens LE.Comparison of FDA table of pharmacogenetic associations and clinical pharmacogenetics implementation consortium guidelines.Am J Health Syst Pharm2022;79:993-1005 PMCID:PMC9171570

[151] Dellefave-Castillo LM,Callis TE.Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing.JAMA Cardiol2022;7:966-74 PMCID:PMC9366660

[152] Mighton C,Uleryk E,Bombard Y.Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis.Genet Med2021;23:22-33

[153] Richards S,Bale S.ACMG Laboratory Quality Assurance CommitteeStandards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med2015;17:405-24 PMCID:PMC4544753

[154] Reuter C,Pariani M.Understanding variants of uncertain significance in the era of multigene panels: through the eyes of the patient.J Genet Couns2019;28:878-86

[155] Wong EK, Bartels K, Hathaway J, et al. Perceptions of genetic variant reclassification in patients with inherited cardiac disease.Eur J Hum Genet2019;27:1134-42 PMCID:PMC6777462

[156] Gordon AS,Venner E.Clinical Annotation Working Group. Frequency of genomic secondary findings among 21,915 eMERGE network participants.Genet Med2020;22:1470-7

[157] McKnight D,Hatchell KE.ELEVIATE ConsortiumGenetic testing to inform epilepsy treatment management from an international study of clinical practice.JAMA Neurol2022;79:1267-76

[158] Lemke AA,Thompson J.Patient-reported outcomes and experiences with population genetic testing offered through a primary care network.Genet Test Mol Biomarkers2021;25:152-60 PMCID:PMC7891215

[159] Sanderson SC,Suckiel SA.Psychological and behavioural impact of returning personal results from whole-genome sequencing: the HealthSeq project.Eur J Hum Genet2017;25:280-92 PMCID:PMC5315514

[160] Abdallaoui OEA, Tornyos D, Lukács R, Szabó D, Komócsi A. Individualized or uniform de-escalation strategies for antiplatelet therapy in acute coronary syndrome: a review of clinical trials with platelet function testing and genetic testing-based protocols.Int J Mol Sci2023;24:9071 PMCID:PMC10219318

[161] Nomura A,Nohara A,Takamura M.Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia.J Clin Lipidol2023;17:622-32

[162] Verdonschot JAJ,Krapels IPC.Implications of genetic testing in dilated cardiomyopathy.Circ Genom Precis Med2020;13:476-87

[163] Bradford WH,Gutierrez-lara EJ.Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics.Nat Cardiovasc Res2023;2:1246-61

[164] van Opbergen CJM,Sacramento CB.AAV-mediated delivery of Plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans.Circ Genom Precis Med2024;17:e004305

[165] Morales A,Sanoudou D.Evolving cardiovascular genetic counseling needs in the era of precision medicine.Front Cardiovasc Med2023;10:1161029 PMCID:PMC10325680

[166] Rickman AF,Spoonamore KG,Helm BM.A descriptive investigation of clinical practice models used by cardiovascular genetic counselors in North America.J Genet Couns2023;32:362-75

[167] Christian S.Principles of genetic counseling in inherited heart conditions.Card Electrophysiol Clin2023;15:229-39

[168] Girolami F,Pálinkás ED.Genetic testing and counselling in hypertrophic cardiomyopathy: frequently asked questions.J Clin Med2023;12:2489 PMCID:PMC10095452

[169] Tromp TR,Wiegman A.Counseling couples at risk of having a child with homozygous familial hypercholesterolemia - clinical experience and recommendations.J Clin Lipidol2023;17:291-6

[170] O'Sullivan JW,Marquez-Luna C.Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association.Circulation2022;146:e93-118 PMCID:PMC9847481

[171] Abraham G,Bhalala OG.Genomic prediction of coronary heart disease.Eur Heart J2016;37:3267-78 PMCID:PMC5146693

[172] Natarajan P,Stitziel NO.Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting.Circulation2017;135:2091-101 PMCID:PMC5484076

[173] Inouye M,Nelson CP.UK Biobank CardioMetabolic Consortium CHD Working GroupGenomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention.J Am Coll Cardiol2018;72:1883-93

[174] O'Sullivan JW,Elliott PM.Polygenic risk scores for the prediction of cardiometabolic disease.Eur Heart J2023;44:89-99

[175] Weindling P.The origins of informed consent: the international scientific commission on medical war crimes, and the Nuremberg code.Bull Hist Med2001;75:37-71

[176] World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects.J Indian Med Assoc2009;107:403-5

[177] Nurmi SM,Moilanen J,Solje E.The ethical implications of genetic testing in neurodegenerative diseases: a systematic review.Scand J Caring Sci2021;35:1057-74

[178] Ascencio-Carbajal T,Navarro-Garcia F.Genetic/genomic testing: defining the parameters for ethical, legal and social implications (ELSI).BMC Med Ethics2021;22:156 PMCID:PMC8609860

[179] Panacer KS.Ethical issues associated with direct-to-consumer genetic testing.Cureus2023;15:e39918 PMCID:PMC10317585

[180] Beig Goharrizi MA, Ghodsi S, Memarjafari MR. Implications of CRISPR-Cas9 genome editing methods in atherosclerotic cardiovascular diseases.Curr Probl Cardiol2023;48:101603

[181] Li ZH,Xu JP,Yang X.Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.Mil Med Res2023;10:12 PMCID:PMC9999643

[182] Morris ZS,Grant J.The answer is 17 years, what is the question: understanding time lags in translational research.J R Soc Med2011;104:510-20 PMCID:PMC3241518

[183] Mathur A,Ameta D,Haranahalli P.Aortic aneurysm.J Transl Int Med2016;4:35-41 PMCID:PMC5290913

[184] Yuan SM.Marfan's syndrome: an overview.Sao Paulo Med J2010;128:360-6 PMCID:PMC10948077

[185] Krahn AD,Sy RW.Congenital long QT syndrome.JACC Clin Electrophysiol2022;8:687-706

[186] Schwartz PJ,Insolia R.Long-QT syndrome: from genetics to management.Circ Arrhythm Electrophysiol2012;5:868-77 PMCID:PMC3461497

[187] Anttonen O,Rissanen H,Viitasalo M.Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population.Circulation2007;116:714-20

[188] Guerrier K,Czosek RJ,Anderson JB.Short QT interval prevalence and clinical outcomes in a pediatric population.Circ Arrhythm Electrophysiol2015;8:1460-4

[189] Pérez-Riera AR,de Rezende Barbosa MPC,de Lucca AA Jr.Catecholaminergic polymorphic ventricular tachycardia, an update.Ann Noninvasive Electrocardiol2018;23:e12512 PMCID:PMC6931575

[190] Krahn AD,Calkins H.Arrhythmogenic right ventricular cardiomyopathy.JACC Clin Electrophysiol2022;8:533-53

[191] Krahn AD,Hamilton R,Laksman Z.Brugada syndrome.JACC Clin Electrophysiol2022;8:386-405

[192] Maron BJ,Nishimura RA.Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review.J Am Coll Cardiol2022;79:372-89

[193] Heymans S,Tschöpe C.Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.Lancet2023;402:998-1011

[194] Fatkin D,Elliott P,Peters S.Contemporary and future approaches to precision medicine in inherited cardiomyopathies: JACC focus seminar 3/5.J Am Coll Cardiol2021;77:2551-72

[195] van der Linde D,Slager MA.Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.J Am Coll Cardiol2011;58:2241-7

[196] Beheshti SO,Varbo A.Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects.J Am Coll Cardiol2020;75:2553-66

[197] Tada H,Inazu A,Mabuchi H.Sitosterolemia, hypercholesterolemia, and coronary artery disease.J Atheroscler Thromb2018;25:783-9 PMCID:PMC6143779

[198] Tada H,Ogura M.Diagnosis and management of sitosterolemia 2021.J Atheroscler Thromb2021;28:791-801 PMCID:PMC8326170

[199] Ruopp NF.Diagnosis and treatment of pulmonary arterial hypertension: a review.JAMA2022;327:1379-91

[200] Rehm HL,Brooks LD.ClinGenClinGen - the clinical genome resource.N Engl J Med2015;372:2235-42 PMCID:PMC4474187